Drug intelligence / Profile preview

ORY-4001

Development stage: Preclinical
Lead developer: Oryzon Genomics
Modality: Small Molecules
Administration: Oral

Overview

ORY-4001 is a selective histone deacetylase 6 (HDAC6) inhibitor developed by Oryzon Genomics. It is an epigenetic experimental drug being investigated for the potential treatment of neurological indications such as amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth (CMT) disease, as well as for rare and orphan diseases through a personalized medicine approach.

Other names: HDAC6 inhibitor (Oryzon Genomics)Oryzon HDAC6 inhibitor

Targets

HDAC6 (Histone deacetylase 6)

Beyond the preview

Go deeper on ORY-4001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORY-4001.

Explore the full profile